GlassScriptPhysician profile
Staci M Hestdalen
NPI 1194790006
$4,891.36
in general payments reported to CMS, 2019-2025
28 companies · $883 in 2025
The $883 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $793 · 2020: $330 · 2021: $445 · 2022: $833 · 2023: $832 · 2024: $777 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,427 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,426.81 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,186.13 | 2019-2025 | |
| Janssen Biotech, INC. | $882.10 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Lilly USA, LLC | $658.14 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $288.73 | 2020-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $227.73 | 2019-2025 | Nemluvio, Oracea |
| Pfizer INC. | $219.19 | 2019-2024 | |
| Leo Pharma INC. | $193.11 | 2022-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $164.11 | 2019-2025 | |
| Amgen INC. | $161.50 | 2019-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $143.85 | 2022-2025 | Sotyktu |
| Merz North America, INC. | $141.90 | 2019 | |
| Sun Pharmaceutical Industries INC. | $114.17 | 2022-2024 | Ilumya |
| Regeneron Healthcare Solutions, INC. | $79.87 | 2019-2025 | Dupixent |
| Genzyme Corporation | $60.64 | 2019-2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $51.45 | 2019-2025 | Siliq |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $49.62 | 2022 | |
| Organon LLC | $30.32 | 2025 | Vtama |
| Dermavant Sciences, INC. | $30.27 | 2023-2024 | Vtama |
| Helsinn Therapeutics (U.S.), INC. | $28.35 | 2019-2021 | |
| Prugen, INC. Pharmaceuticals | $24.80 | 2019 | |
| Verrica Pharmaceuticals INC. | $24.72 | 2023 | Ycanth |
| Lemaitre Vascular, INC. | $22.12 | 2024 | Hydro Lemaitre Valvulotome |
| Genentech USA, INC. | $22.11 | 2023 | Xolair |
| Celgene Corporation | $20.81 | 2019 | |
| Allergan, INC. | $20.01 | 2022 | |
| Strata Skin Sciences, INC. | $18.14 | 2023 | Xtrac |
| Incyte Corporation | $15.14 | 2023 | Opzelura |
| Dusa Pharmaceuticals, INC. | $12.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Staci Hestdalen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.